构建可持续发展的中国医药创新生态系统 - 中国外商投资企业协会药品 .pdfVIP

Fostering a Sustainable Ecosystem for Drug Innovation in China 构建可持续发展的中国 医药创新生态系统 China Pharmaceutical Enterprises Association (CPEA) 中国医药企业管理协会 China Pharmaceutical Industry Association (CPIA) 中国化学制药工业协会 China Chamber of Commerce for Import Export of 中国医药保健品进出口商会 Medicines Health Products (CCCMHPIE) RD-based Pharmaceutical Association Committee 中国外商投资企业协会药品研制 (RDPAC) 和开发行业委员会 October 2016 2016年10月 FOREWORD Pursuing innovation-driven development is a core strategy in China’s 13th Five-year Plan, and the bio-pharma industry is one of the pillars. Bio-pharma innovation not only provides a long-term growth engine for the economy but also is a fundamental requirement for improving people’s well-being. Globally, a vibrant and competitive drug innovation industry requires a healthy ecosystem featuring a virtuous cycle. Drug innovation is characterized by long development cycles, high risks, and large investments, thus, policy, capability and investment are three indispensable and interacting elements in the ecosystem. Specifically, policy environment remains at the core of the ecosystem. A policy environment that encourages innovation can ensure a well- functioning market mechanism, thereby boosting capital and capabilities needed to translate technology into innovative products. China’s drug innovation ecosystem has begun to take shape. Over the past two years, the aforementioned three elements of policy, capabilities and investment have been significantly improved, forming a virtuous cycle. Thanks to the improving policy environment, especially regulatory reform, private capital inflow has increased rapidly and the industry is attracting an increasing number of high-caliber professionals. These developments have allowed China’s bio-pharma industry to be well poised to drive innovation. In the next 10 to 20 years, establishing a sustainable ecosystem for drug